Mereo BioPharma Group plc - Sponsored ADR

MREO Healthcare Biotechnology

Mereo BioPharma Group plc - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $500,000.00, down 95.0% from fiscal 2023. In the quarter to June 2026, EPS grew 52.3% and free cash flow grew 21.0%, each against the same quarter a year earlier.

0.30 0.01 −3.23%
Market cap
$49.3M
P/E
0.0×
Fwd P/E
−8.3×
Dividend yield
—
F-score
n/a
Altman Z
−9.11
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
5.88 6.48 10.46 8.71
Net Debt/EBITDA
4.39 4.21 5.37 4.62
Debt/Equity
0.00 0.00 0.00 0.01
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.04) (0.03) (0.05) (0.05)
Book value per Share
0.18 0.21 0.26 0.29
Free Cash Flow
(6.04) (4.61) (7.68) (7.31)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates